|
|
|
| Development and Application of Ang2 Quantitative Assay Kit |
| WANG Hong1,QIU Yu,rong2,WANG Jun3,WANG Chun-zhi1,LIANG Zhen-xing1,WANG Shan-shan1 |
1.Guangdong Hongye Antibody Science&Technology Co., Ltd., Guangzhou 510663, China
2.Southern Hospital, Guangzhou 510515, China
3.Guangdong NO.2 Provincial People’s Hospital,Guangzhou 510317, China |
|
|
|
Abstract Angiopoietin-2(Ang-2) was a specific vasular growth stimulating factor. It could be highly expressed in malignant tumor cell only, and had a close affinity with the amount of tumor vessel. So it could be used to make prognosis as serum marker. Serum Ang-2 quantitative detection may be helpful for malignant tumor diagnosis and pathogenic mechanism research. A Ang-2 chemiluminesscence quantitative assay kit was developed based on the recombinant Ang-2 antigen expressed in E.coli and the Ang-2 monoclonal antibodies selected from Ang-2 antigen immunizing mice. Several characteristics of the Ang-2 quantitative assay kit were analyzed. The recombinant Ang-2 protein purity was ≥92%. The sensibility of the Ang-2 quantitative assay kit is 0.1ng/ml, the linearity range of it is 0.5-25ng/ml. No coss-reactions to lipoprotein, GLB, α1-acid glycoprotein, HGB, mucoprotein, hyaluronic acid or CEA were observed. The addition accuracy was between 97.6%-102.7%. CV (within batch) ≤4.1%, CV (batch to batch) ≤8.6%. After be kept in 37℃ for 4 days, the technical datas were almost same as be kept in 4℃. At last， the Ang-2 quantitative assay kit was use to detecte the Ang-2 in 307 gynecology malignant tumor patients’ serum and 1000 healthy people’s serum. 73.2% cervical carcinoma patients, 83.3% oophoroma patients, 76.7% endometrial carcinoma patients and 70.4% other gynecology malignant tumor patients can be detected. All the results showed that the Ang-2 quantitative assay kit we developed can be used for gynecology malignant tumor diagnosis and pathogenic mechanism research.
|
|
Received: 05 November 2009
Published: 27 January 2010
|
|
|
| ［1］ Maisonpierne P C, Suri C, Jones P F, et al. Angiopoietin2 a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science , 1997,277(7):5560.
［2］ Kim I J, Kim J H, Ryu Y S, et al. Characterization and Expression of a Novel Alternatively Spliced Human Angiopoietin2. J Biol Chem, 2000 ,275 (24): 1855018556.
［3］ Jones N, Master Z, Jones J, et al. Identification of TekTie2 binding partners binding to a multifunctional dockingsite mediates cell survival and migration. J Biol Chem, 1999, 274(10): 3089630905.
［4］ Suri C, Mcclain J,Thurston G, et al. Increased Vascularization in Mice Overexpressing Angiopoietin1. Science, 1998, 282(16): 468471.
［5］ Fadel B M, Boute S C, Quertermous T. Functional analysisi of the endothelial cellspecific Tie2/Tek promoter identifies unique proteinbinding elements. Biochem J, 1998, 330(Pt1): 335343.
［6］ Kampfer H, Pfeischifter J, Frank S, et al. Expression regulation of angiopoietin1 and 2 and the tie1 and 2 receptor tyrosine kinases during cutaneoue wound healing: a comparative study of normal and impaired repaire. Lab Invest, 2001, 81 (3): 361373.
［7］ Siobhan L, Thomas N. Sato Angiopoietin and Tie signaling pathways in vascular development. Matrix Biology, 2001, 20(9):319325.
［8］ Teichert K K, Maisonpierre P C, Jones N, et al. Biological action of angiopoietin2 in a fibrin matrix model of angiogenesis is accociated with activation of tie2. Cardiorasc Res, 2001, 49 (3): 659670.
［9］ Xing L H, Zhang Z X, Xu Y J. Expression of angiopoietin2 gene in nonsmall cell lung cancer. J Huazhong Univ Sci Technolog Med Sci, 2003, 23(4): 362.
［10］ Etoh T, Inoue H, Tanaka S J, et al. Angiopoietin2 is related to tumor angiogenesis in gastric carcinoma possible in vivo regulation via induction of proteases. Cancer Res, 2001, 61 (5): 2145.
［11］ Torimura T, Ueno T, Kin M, et al. Overexpression of angiopoietin1 and angiopoietin2 in hepatocellular carcinoma. J Hepatol, 2004, 40(5): 799.
［12］ 谢南，王珊珊，王虹等. 乙型肝炎病毒X蛋白定量试验与临床研究. 中国生物工程杂志，2009, 29(9): 6167. Xie N, Wang S S, Wang H, et al. China Biotechnology, 2009, 29(9): 6167. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
